Literature DB >> 18787404

The fold recognition of CP2 transcription factors gives new insights into the function and evolution of tumor suppressor protein p53.

Katarzyna Kokoszynska1, Jerzy Ostrowski, Leszek Rychlewski, Lucjan S Wyrwicz.   

Abstract

The CP2 transcription factor (TFCP2) is a critical regulator of erythroid gene expression. Apart from the involvement in the transcriptional switch of globin gene promoters it activates an array of cellular and viral gene promoters. A number of homologous proteins was identified in genomes of Metazoa, with additional five homologues encoded by the human genome (TFCP2L1, UBP1, GRHL1, GRHL2, GRHL3). Although several experimental studies have already been published, the knowledge on the molecular mechanism of activity of this transcription factors remains very limited. Here we present the application of fold recognition and protein structure prediction in drafting the structure-to-function relationship of the CP2 family. The employed procedure clearly shows that the family adopts a DNA binding immunoglobulin fold homologous to the p53 (TP53) core domain, and a novel type of ubiquitin-like domain and a sterile alpha motif (SAM) form oligomerization modules. With a traceable evolution of CP2 family throughout the Metazoa group this protein family is highly likely to represent an ancestor of the critical cell cycle regulator p53. Based on this observation several functional hypotheses on structure-to-function relationship of p53 were drawn. The DNA motif recognized by p53 is a result of further specialization of the CP2 DNA-binding module. The analysis also shows the critical role of protein oligomerization for the function of this protein superfamily. Finally, the identification of distant homologs of TP53 allowed performing a phylogenetic footprinting analysis explaining the role of the specific amino acids important for both - the protein folding and the binding of DNA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18787404     DOI: 10.4161/cc.7.18.6680

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  23 in total

Review 1.  Roles of Grainyhead-like transcription factors in cancer.

Authors:  S M Frisch; J C Farris; P M Pifer
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

Review 2.  Recent discoveries concerning the involvement of transcription factors from the Grainyhead-like family in cancer.

Authors:  Michal Mlacki; Agnieszka Kikulska; Ewa Krzywinska; Magdalena Pawlak; Tomasz Wilanowski
Journal:  Exp Biol Med (Maywood)       Date:  2015-06-10

3.  The transcription factor LSF: a novel oncogene for hepatocellular carcinoma.

Authors:  Prasanna K Santhekadur; Devaraja Rajasekaran; Ayesha Siddiq; Rachel Gredler; Dong Chen; Scott E Schaus; Ulla Hansen; Paul B Fisher; Devanand Sarkar
Journal:  Am J Cancer Res       Date:  2012-04-21       Impact factor: 6.166

4.  The evolutionary diversification of LSF and Grainyhead transcription factors preceded the radiation of basal animal lineages.

Authors:  Nikki Traylor-Knowles; Ulla Hansen; Timothy Q Dubuc; Mark Q Martindale; Les Kaufman; John R Finnerty
Journal:  BMC Evol Biol       Date:  2010-04-18       Impact factor: 3.260

5.  Distant homologs of anti-apoptotic factor HAX1 encode parvalbumin-like calcium binding proteins.

Authors:  Katarzyna Kokoszyńska; Leszek Rychlewski; Lucjan S Wyrwicz
Journal:  BMC Res Notes       Date:  2010-07-15

Review 6.  Grainyhead-like 2 as a double-edged sword in development and cancer.

Authors:  Jiaxing He; Chunyang Feng; He Zhu; Shuying Wu; Peng Jin; Tianmin Xu
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

7.  Grainyhead-like 2 (GRHL2) distribution reveals novel pathophysiological differences between human idiopathic pulmonary fibrosis and mouse models of pulmonary fibrosis.

Authors:  Saaket Varma; Poornima Mahavadi; Satish Sasikumar; Leah Cushing; Tessa Hyland; Ann E Rosser; Daniela Riccardi; Jining Lu; Tanya V Kalin; Vladimir V Kalinichenko; Andreas Guenther; Maria I Ramirez; Annie Pardo; Moisés Selman; David Warburton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-12-27       Impact factor: 5.464

8.  Transcription factors LSF and E2Fs: tandem cyclists driving G0 to S?

Authors:  Ulla Hansen; Laura Owens; Utsav H Saxena
Journal:  Cell Cycle       Date:  2009-07-21       Impact factor: 4.534

9.  Antiproliferative small-molecule inhibitors of transcription factor LSF reveal oncogene addiction to LSF in hepatocellular carcinoma.

Authors:  Trevor J Grant; Joshua A Bishop; Lisa M Christadore; Girish Barot; Hang Gyeong Chin; Sarah Woodson; John Kavouris; Ayesha Siddiq; Rachel Gredler; Xue-Ning Shen; Jennifer Sherman; Tracy Meehan; Kevin Fitzgerald; Sriharsa Pradhan; Laura A Briggs; William H Andrews; Devanand Sarkar; Scott E Schaus; Ulla Hansen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-06       Impact factor: 11.205

10.  HORIBALFRE program: Higher Order Residue Interactions Based ALgorithm for Fold REcognition.

Authors:  Pandurangan Sundaramurthy; Raashi Sreenivasan; Khader Shameer; Sunita Gakkhar; Ramanathan Sowdhamini
Journal:  Bioinformation       Date:  2011-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.